- Home
- XLO vs DYAI Comparison
XLO vs DYAI Comparison
Compare XLO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- DYAI
- Stock Information
- Founded
- XLO 2016
- DYAI 1979
- Country
- XLO United States
- DYAI United States
- Employees
- XLO N/A
- DYAI N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XLO Health Care
- DYAI Health Care
- Exchange
- XLO Nasdaq
- DYAI Nasdaq
- Market Cap
- XLO 35.7M
- DYAI 30.2M
- IPO Year
- XLO 2021
- DYAI 2004
- Fundamental
- Price
- XLO $0.66
- DYAI $0.94
- Analyst Decision
- XLO Buy
- DYAI Strong Buy
- Analyst Count
- XLO 2
- DYAI 1
- Target Price
- XLO $3.00
- DYAI $6.00
- AVG Volume (30 Days)
- XLO 341.9K
- DYAI 213.1K
- Earning Date
- XLO 08-19-2025
- DYAI 08-13-2025
- Dividend Yield
- XLO N/A
- DYAI N/A
- EPS Growth
- XLO N/A
- DYAI N/A
- EPS
- XLO N/A
- DYAI N/A
- Revenue
- XLO $9,274,000.00
- DYAI $3,554,344.00
- Revenue This Year
- XLO $300.08
- DYAI $22.56
- Revenue Next Year
- XLO $1.87
- DYAI $30.95
- P/E Ratio
- XLO N/A
- DYAI N/A
- Revenue Growth
- XLO N/A
- DYAI 57.59
- 52 Week Low
- XLO $0.62
- DYAI $0.91
- 52 Week High
- XLO $1.70
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- XLO 42.53
- DYAI 40.23
- Support Level
- XLO $0.62
- DYAI $0.97
- Resistance Level
- XLO $0.70
- DYAI $1.04
- Average True Range (ATR)
- XLO 0.04
- DYAI 0.09
- MACD
- XLO -0.00
- DYAI -0.02
- Stochastic Oscillator
- XLO 46.15
- DYAI 6.92
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.